📊 BNTX Key Takeaways
Is BioNTech SE (BNTX) a Good Investment?
Unable to provide meaningful fundamental analysis due to complete absence of financial data. All key metrics including revenue, profitability, balance sheet items, and cash flow are unavailable, preventing assessment of financial health or operational performance.
BioNTech’s financial health remains strong, anchored by approximately €17.2 billion of cash, cash equivalents, and security investments at December 31, 2025, which gives it unusual flexibility to fund heavy oncology R&D and absorb losses. However, fundamental earnings quality is mixed: 2025 revenue rose to about €2.87 billion largely because of Bristol Myers Squibb collaboration revenue, while IFRS net loss widened to about €1.14 billion and core COVID vaccine demand continues to soften.
Why Buy BioNTech SE Stock? BNTX Key Strengths
- No strengths identified
- Exceptional liquidity and balance-sheet flexibility, with roughly €17.2 billion in cash, cash equivalents, and security investments at year-end 2025
- Deep investment capacity in oncology, supported by multiple late-stage programs, active portfolio management, and BMS cost sharing
- Adjusted 2025 loss was far smaller than IFRS loss, indicating legal settlements and one-time charges were a major drag rather than pure operating deterioration
BNTX Stock Risks: BioNTech SE Investment Risks
- No financial data available for analysis
- Inability to assess profitability or operational efficiency
- No visibility into balance sheet strength or liquidity position
- Cannot evaluate cash generation or capital allocation
- Zero insider trading activity in last 90 days suggests no recent insider conviction
- Profitability has deteriorated sharply from prior vaccine-era earnings, with BioNTech reporting IFRS net losses in both 2024 and 2025
- Revenue growth quality is uneven because 2025 growth was driven mainly by collaboration revenue rather than broad-based recurring product expansion
- 2026 outlook implies lower COVID vaccine revenue and no expected oncology product sales yet, leaving execution dependent on pipeline readouts and future approvals
Key Metrics to Watch
- Quarterly revenue and revenue growth rates
- Operating margins and profitability metrics
- Cash position and cash flow generation
- Balance sheet health and debt levels
- R&D spending and pipeline advancement
- Insider buying activity
- Quarterly non-COVID collaboration and product revenue mix versus declining COVID vaccine contribution
- R&D efficiency and operating loss trajectory relative to late-stage clinical milestones and cash burn
BioNTech SE (BNTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BNTX Profit Margin, ROE & Profitability Analysis
BNTX vs Healthcare Sector: How BioNTech SE Compares
How BioNTech SE compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioNTech SE Stock Overvalued? BNTX Valuation Analysis 2026
Based on fundamental analysis, BioNTech SE has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioNTech SE Balance Sheet: BNTX Debt, Cash & Liquidity
BNTX Revenue Growth, EPS Growth & YoY Performance
BNTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioNTech SE (CIK: 0001776985)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BNTX
What is the AI rating for BNTX?
BioNTech SE (BNTX) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 44% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BNTX's key strengths?
Claude: . ChatGPT: Exceptional liquidity and balance-sheet flexibility, with roughly €17.2 billion in cash, cash equivalents, and security investments at year-end 2025. Deep investment capacity in oncology, supported by multiple late-stage programs, active portfolio management, and BMS cost sharing.
What are the risks of investing in BNTX?
Claude: No financial data available for analysis. Inability to assess profitability or operational efficiency. ChatGPT: Profitability has deteriorated sharply from prior vaccine-era earnings, with BioNTech reporting IFRS net losses in both 2024 and 2025. Revenue growth quality is uneven because 2025 growth was driven mainly by collaboration revenue rather than broad-based recurring product expansion.
What is BNTX's revenue and growth?
BioNTech SE reported revenue of N/A.
Does BNTX pay dividends?
BioNTech SE does not currently pay dividends.
Where can I find BNTX SEC filings?
Official SEC filings for BioNTech SE (CIK: 0001776985) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BNTX's EPS?
BioNTech SE has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BNTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BioNTech SE has a HOLD rating with 44% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BNTX stock overvalued or undervalued?
Valuation metrics for BNTX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BNTX stock in 2026?
Our dual AI analysis gives BioNTech SE a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BNTX's free cash flow?
BioNTech SE's operating cash flow is N/A, with capital expenditures of N/A.
How does BNTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).